Browsing Research publications by Author "Geisler, Tobias"
Now showing items 1-5 of 5
-
The East Asian Paradox : An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease
Kim, Hyun Kuk; Tantry, Udaya S.; Smith, Sidney C.; Jeong, Myung Ho; Park, Seung Jung; Kim, Moo Hyun; Lim, Do Sun; Shin, Eun Seok; Park, Duk Woo; Huo, Yong; Chen, Shao Liang; Bo, Zheng; Goto, Shinya; Kimura, Takeshi; Yasuda, Satoshi; Chen, Wen Jone; Chan, Mark; Aradi, Daniel; Geisler, Tobias; Gorog, Diana A.; Sibbing, Dirk; Lip, Gregory Y.H.; Angiolillo, Dominick J.; Gurbel, Paul A.; Jeong, Young Hoon (2020-11-10)East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12receptor inhibitors (e.g., ticagrelor and prasugrel) and ... -
Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: A Pandora Box to Explain Prognostic Differences
Kim, Hyun Kuk; Tantry, Udaya S.; Park, Hyun-Woong; Geisler, Tobias; Gorog, Diana; Gurbel, Paul A; Jeong, Young-Hoon (2021-03-01)Arterial and venous atherothrombotic events are finely regulated processes involving acomplex interplay between vulnerable blood, vulnerable vessel, and blood stasis.Vulnerable blood (‘thrombogenicity’) comprises complex ... -
Platelet inhibition in acute coronary syndrome and PCI: Insights from the past and present
Gorog, Diana; Geisler, Tobias (2020-01-19)Platelet activation and aggregation have a pivotal role in arterial thrombosis and in the pathogenesis of both acute coronary syndromes (ACS) and in the thrombotic complications that occur in patients undergoing percutaneous ... -
Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
Farag, Mohamed; Jeyalan, Visvesh; Ferreiro, Jose Luis; Jeong, Young-Hoon; Geisler, Tobias; Gorog, Diana A. (2022-10-20)Current guidelines for patients with acute coronary syndrome (ACS) recommend dual antiplatelet therapy (DAPT) for 12 months. Since bleeding is the main Achilles' heel of DAPT, in recent years several randomized controlled ... -
Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice
Geisler, Tobias; Jorbenadze, Rezo; Popov, Aron-Frederik; Mueller, Karin L.; Rath, Dominik; Droppa, Michal; Schreieck, Juergen; Seizer, Peter; Storey, Robert F.; Kristensen, Steen D.; Rubboli, Andrea; Gorog, Diana; Aradi, Daniel; Sibbing, Dirk; Huber, Kurt; Gawaz, Meinrad; Berg, Jur Ten (2019-08-17)As the number of, and the indications for, structural heart interventions are increasing worldwide, the optimal secondary prevention to reduce device thrombosis is becoming more important. To date, most of the recommendations ...